Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 01-Jul 2024. Module: IPS terminology module (core metadata concept)
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 4696188010 | Pyrimethamine 12.5 mg and sulfadoxine 250 mg tablet for oral suspension | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | IPS terminology module (core metadata concept) |
| 4696189019 | Product containing precisely pyrimethamine 12.5 milligram and sulfadoxine 250 milligram/1 each tablet for conventional release oral suspension (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | IPS terminology module (core metadata concept) |
| 5259839015 | Pyrimethamine 12.5 mg and sulfadoxine 250 mg dispersible oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | IPS terminology module (core metadata concept) |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely pyrimethamine 12.5 milligram and sulfadoxine 250 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Is a | Product containing only pyrimethamine and sulfadoxine (medicinal product) | true | Inferred relationship | Some | ||
| Product containing precisely pyrimethamine 12.5 milligram and sulfadoxine 250 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has manufactured dose form | Tablet for conventional release oral suspension (dose form) | true | Inferred relationship | Some | ||
| Product containing precisely pyrimethamine 12.5 milligram and sulfadoxine 250 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has unit of presentation | Tablet (unit of presentation) | true | Inferred relationship | Some | ||
| Product containing precisely pyrimethamine 12.5 milligram and sulfadoxine 250 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has basis of strength substance (attribute) | Pyrimethamine (substance) | true | Inferred relationship | Some | 1 | |
| Product containing precisely pyrimethamine 12.5 milligram and sulfadoxine 250 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 1 | |
| Product containing precisely pyrimethamine 12.5 milligram and sulfadoxine 250 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Some | 1 | |
| Product containing precisely pyrimethamine 12.5 milligram and sulfadoxine 250 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has precise active ingredient | Pyrimethamine (substance) | true | Inferred relationship | Some | 1 | |
| Product containing precisely pyrimethamine 12.5 milligram and sulfadoxine 250 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has basis of strength substance (attribute) | Sulfadoxine | true | Inferred relationship | Some | 2 | |
| Product containing precisely pyrimethamine 12.5 milligram and sulfadoxine 250 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 2 | |
| Product containing precisely pyrimethamine 12.5 milligram and sulfadoxine 250 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Some | 2 | |
| Product containing precisely pyrimethamine 12.5 milligram and sulfadoxine 250 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has precise active ingredient | Sulfadoxine | true | Inferred relationship | Some | 2 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
Reference Sets
FHIR